Editors note: This article was updated on 18 December to reflect European and US regulatory approval for Novo Holdings acquisition of Catalent.
Variability across experiences stems from clinician review, pharmacy availability, and membership terms rather than fixed program promises
Conclusions In this large cohort study, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with the use of DPP-4 inhibitors or SGLT-2 inhibitors in patients with type 2 diabetes
Access and Affordability of Semaglutide Through PlexusDx PlexusDx provides compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan across all commitment tiersno insurance required, no membership fee, and HSA/FSA eligible
In a randomized, controlled clinical study (Study F), in adult patients with type 2 diabetes not using oral antidiabetic medications (n = 518), a basal-bolus regimen of insulin glargine once daily at bedtime or NPH insulin administered once or twice daily was evaluated for 28 weeks